Cesca Therapeutics to Present & Exhibit at the ISCT North America 2016 Regional Meeting
September 27 2016 - 6:00AM
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based
regenerative medicine company, today announced that Dalip Sethi,
Ph.D., Director of Clinical Research, will be presenting at the
2016 International Society for Cellular Therapy (ISCT) North
America Regional Meeting, to be held from September 30 to October
2, 2016 at the Peabody Hotel in Memphis, Tennessee. The company
will also be exhibiting at the meeting in Booth 215.
“We are very pleased to present and exhibit at
the ISCT regional meeting, which brings together many of the
world’s leading scientists, clinicians and regulatory experts in
cell therapy,” stated Dalip Sethi, Ph.D., Director of Clinical
Research at Cesca Therapeutics. “It is always an exciting
experience to share our recent research and advances in our
technology with other experts in the field and to develop new
collaborative relationships with innovative organizations.”
Details for the Company presentation are as
follows:
Location: |
Peabody
Hotel in Memphis, Tennessee |
Date: |
Friday,
September 30, 2016 |
Time: |
7:30 -
8:30 AM |
Room: |
Venetian
Room |
The ISCT is a global society of clinicians,
regulators, technologists, and industry partners with a shared
vision to translate cellular therapy into safe and effective
therapies that improve patients’ lives. ISCT members gain access to
an influential global community of peers, experts, and
organizations invested in cell therapy. ISCT offers a unique
collaboration between academia, regulatory bodies, and industry
partners in cell therapy translation.
Detailed program at ISCT North America
2016
http://www.isct-na2016.com/wp-content/uploads/2016/09/ISCTNA-2016Program_Web.pdf
About Cesca Therapeutics
Inc.Cesca Therapeutics Inc. (www.cescatherapeutics.com) is
engaged in the research, development, and commercialization of
cellular therapies and delivery systems for use in regenerative
medicine. The Company is a leader in the development and
manufacture of automated blood and bone marrow processing systems
that enable the separation, processing and preservation of cell and
tissue therapeutics. These include:
- The SurgWerks™ System (in development) - a
proprietary system comprised of the SurgWerks Processing Platform,
including devices and analytics, and indication-specific SurgWerks
Procedure Kits for use in regenerative stem cell
therapy at the point-of-care for vascular and orthopedic
diseases.
- The CellWerks™ System (in development) - a
proprietary cell processing system with associated analytics for
intra-laboratory preparation of adult stem cells from bone marrow
or blood.
- The AutoXpress® System (AXP®) - a proprietary
automated device and companion sterile disposable for concentrating
hematopoietic stem cells from cord blood.
- The MarrowXpress™ System
(MXP™) - a derivative product of the AXP and its accompanying
sterile disposable for the isolation and concentration of
hematopoietic stem cells from bone marrow.
- The BioArchive® System - an automated
cryogenic device used by cord blood banks for the cryopreservation
and storage of cord blood stem cell concentrate for future
use.
- Manual bag sets for use in the processing and
cryogenic storage of cord blood.
Forward-Looking Statements and Safe
Harbor Statement under the Private Securities Litigation Reform Act
of 1995This press release includes statements of future
expectations and other forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based on
management’s current views and assumptions, speak only as of the
date hereof and are subject to change. Forward-looking
statements can often be identified by words such as “may,” “could,”
“potential,” “continue,” and similar expressions and include, but
are not limited to, statements regarding research and product
commercialization. These forward-looking statements are not
guarantees of future results and are subject to known and unknown
risks and uncertainties that could cause actual results,
performance or events to differ materially and adversely from those
expressed or implied in such statements. A more complete
description of risks that could cause actual events to differ from
the outcomes predicted by these forward-looking statements is set
forth under the caption "Risk Factors" in our Annual Report on Form
10-K, in our Quarterly Reports on Form 10-Q, and in other reports
filed with the Securities and Exchange Commission from time to
time, and you should consider each of those factors when evaluating
the forward-looking statements. We undertake no obligation to
revise or update publicly any forward-looking statements for any
reason, except as required by law.
Company Contact: Cesca Therapeutics Inc.
ir@cescatherapeutics.com
Investor Contact: The Ruth Group
Lee Roth / Tram Bui
646-536-7012 / 7035
lroth@theruthgroup.com / tbui@theruthgroup.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2023 to Apr 2024